Taspine downregulates VEGF expression and inhibits proliferation of vascular endothelial cells through PI3 kinase and MAP kinase signaling pathways

Biomedicine and Pharmacotherapy

Volumn 62, Issue 6, 2008, Pages 383-389

  Zhao, Jing ^a   Zhao, Le ^a   Chen, Wei ^a   He, Langchong ^a   Li, Xu ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

HUVECs; MAP kinase pathway; PI3 kinase pathway; Taspine; VEGF

Indexed keywords

MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PLANT MEDICINAL PRODUCT; PROTEIN KINASE B; TASPINE; VASCULOTROPIN; VASCULOTROPIN 165; VASCULOTROPIN RECEPTOR 2;

ARTICLE; CAULOPHYLLUM; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENDOTHELIUM CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION; VASCULAR ENDOTHELIUM;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ALKALOIDS; ANGIOGENESIS INHIBITORS; CELL LINE; CELL PROLIFERATION; DOWN-REGULATION; DRUGS, CHINESE HERBAL; ENDOTHELIUM, VASCULAR; HUMANS; MAP KINASE SIGNALING SYSTEM; PHOSPHORYLATION; RNA, MESSENGER; SIGNAL TRANSDUCTION; UMBILICAL VEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 46049090571     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2007.07.013     Document Type: Article

References (33)

1. Fidler I.J., and Ellis L.M. The implication of angiogenesis for the biology and therapy of cancer metastasis. Cell 79 (1994) 185-188
2. Folkmon J. Clinical applications of research on angiogenesis. N Engl J Med 333 (1995) 1757-1763
3. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1 (1995) 27-31
4. O'Reilly M.S., Holmgren L., Shing Y., Chen C., Rosenthal R.A., Moses M., et al. Angiostatin: a novel angiogenesis inhibitor, that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79 (1994) 315-328
5. Poste G., and Fidler I.J. The pathogenesis of cancer metastasis. Nature 283 (1980) 139-146
6. Takeda A. Role of angiogenesis in the development and growth of liver metastasis. Ann Surg Oncol 9 (2002) 610-616
7. Bates D.O., Hillman N.J., Williams B., Neal C.R., and Pocock T.M. Regulation of microvascular permeability by vascular endothelial growth factors. J Anat 200 (2002) 581-597
8. Ferrara N. Role of vascular endothelial growth factor in physiological and pathological conditions: therapeutic implications. Semin Oncol 29 (2002) 10-14
9. Claffey K.P., Brown L.F., del Aguila L.F., Tognazzi K., Yeo K.T., Manseau E.J., et al. Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis and experimental metastasis. Cancer Res 56 (1996) 176-181
10. Senger D.R., Van de Water L., Brown L.F., Nagy J.A., Yeo K.T., Yeo T.K., et al. Vascular permeability factor (VEGF, VPF) in tumor biology. Cancer Metastasis Rev 12 (1993) 303-324
11. Rudlowski C., Pickart A.K., Fuhljahn C., Friepoertner T., Schlehe B., Biesterfeld S., et al. Prognostic significance of vascular endothelial growth factor expression in ovarian cancer patients: a long-term follow-up. Int J Gynecol Cancer 16 (2006) 183-189
12. Brustmann H., and Naude S. Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with high mitotic activity and high FIGO stage. Gynecol Oncol 84 (2002) 47-52
13. Brekken R.A., and Thorpe P.E. Vascular endothelial growth factor and vascular targeting of solid tumors. Anticancer Res 21 (2001) 4221-4229
14. Rosen L.S. VEGF-targeted therapy: therapeutic potential and recent advances. Oncologist 10 (2005) 382-391
15. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
16. Rugo H.S., Herbst R.S., Liu G., Park J.W., Kies M.S., Steinfeldt H.M., et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 23 (2005) 5474-5483
17. Yiping L., and Langchong H. Establishing and preliminary application of vascular endothelial cell membrane chromatography. Chin Sci Bull 52 (2007) 410-415
18. Perdue G.P., Blomster R.N., Blake D.A., and Farnsworth N.R. South American plants II: taspine isolation and anti-inflammatory activity. J Pharm Sci 68 (1979) 124-126
19. Vaisberg A.J., Milla M., Planas M.C., Cordova J.L., Agusti E.R., Ferrevra R., et al. Taspine is the cicatrizant principle in sangre de grado extracted from Croton lechleri. Planta Med 55 (1989) 140-143
20. Coultas L., Chawengsaksophak K., and Rossant J. Endothelial cells and VEGF in vascular development. Nature 438 (2005) 937-945
21. Itokawa H., Ichihara Y., Mochizuki M., Enomori T., Morita H., Shirota H., et al. A cytotoxic substance from sangre de grado. Chem Pharm Bull 39 (1991) 1041-1042
22. Marme D. Tumor angiogenesis: the pivotal role of vascular endothelial growth factor. World J Urol 14 (1996) 166-174
23. Samoto K., Ikezaki K., Ono M., Shono T., Kohno K., Kuwano M., et al. Expression of vascular endothelial growth factor and its possible relation with neovascularization in human brain tumors. Cancer Res 55 (1995) 1189-1193
24. Takahashi Y., Kitadai Y., Bucana C.D., Cleary K.R., and Ellis L.M. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 55 (1995) 3964-3968
25. Weidner N., Carroll P.R., Flax J., Blumenfeld W., and Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 143 (1993) 401-409
26. Akahashi T., and Shibuya M. The 230kDa mature form of KDR/Flk-1 (VEGF receptor-2) activates the PLC-γ pathway and partially induces mitotic signals in NIH3T3 fibroblasts. Oncogene 14 (1997) 2079-2089
27. Johnson G.L., and Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298 (2002) 1911-1912
28. Gonzalez F.A., Raden D.L., Rigby M.R., and Davis R.J. Heterogeneous expression of four MAP kinase isoforms in human tissues. FEBS Lett 304 (1992) 170-178
29. Zhou G., Bao Z.Q., and Dixon J.E. Components of a new human protein kinase signal transduction pathway. J Biol Chem 270 (1995) 12665-12669
30. Cantley L.C. The phosphoinositide 3-kinase pathway. Science 296 (2002) 1655-1657
31. Dimmeler S., and Zeiher A.M. Akt takes center stage in angiogenesis signaling. Circ Res 86 (2000) 4-5
32. Gerber H.P., McMurtrey A., Kowalski J., Yan M., Keyt B.A., Dixit V., et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 273 (1998) 30336-30343
33. Thakker G.D., Hajjar D.P., Muller W.A., and Rosengart T.K. The role of phosphatidylinositol3-kinase in vascular endothelial growth factor signaling. J Biol Chem 274 (1999) 10002-10007